---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210428"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:35:43.730559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline

## Summary
- Net loss of $15.0M ($0.11 per share) vs $28.5M ($0.20) a year ago; revenue from AstraZeneca collaboration $0.4M.
- Cash, cash equivalents & short-term investments at $70.1M as of March 31, 2026.
- R&D expenses fell to $9.1M from $20.8M, primarily due to zerlasiran Phase 3 readiness completed in 2025.
- Phase 2 SANRECO trial of divesiran for polycythemia vera ongoing; topline results expected August 2026.
- Phase 1 abstracts for divesiran (EHA) and SLN312/AZD1705 (EAS) accepted for upcoming congress presentations.

## SEC filing metadata
- accession: 0001193125-26-210428
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/sln-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210428
- JSON: https://secwatch.observer/filing/0001193125-26-210428.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210428.txt

## Source-grounded claims
- claim_id: b72c2d50ab8cc026011baad4bd52ca7f32d2fa11
  claim: Silence Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income Net loss was $15.0 million, or $0.11 basic and diluted net loss per share, EPS $0.11 basic and diluted net loss per share.
  evidence_excerpt: cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.